Search Results
Your search for ,aLl matches 18309 pages
Showing 201 - 250Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer?
Mutations in KDM6A have been identified as a regulator of therapeutic responses in advanced bladder cancer, sensitizing tumors to anti–PD-1 immune checkpoint inhibition but resisting cisplatin chemotherapy, according to early research published in Nature Communications. Based on this and further...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
An artificial saliva in the form of a mouthwash, produced with a protein extracted from sugarcane and modified in a laboratory, may aid in treating hyposalivation among patients with head and neck cancer, a new study has found. Radiotherapy delivered very close to the mouth can destroy salivary...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by Harter et al, the final results of a European phase III trial (AGO-OVAR 2.29/ENGOT-ov34) showed no significant overall or progression-free survival benefit with the addition of atezolizumab to bevacizumab and nonplatinum chemotherapy in patients...
Using AI to Ensure That All Patients With Cancer Have Access to Precision Oncology Care
Steve Brown, Founder and Chief Executive Officer of CureWise (curewise.com), an artificial intelligence (AI)-driven patient advocacy app, describes his year-long quest to understand a series of symptoms that ultimately led to a diagnosis of light chain (AL) amyloidosis—a disease closely related to ...
Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma
As reported in The Lancet by Falchi et al, an interim analysis of the phase III EPCORE FL-1 trial has shown that the addition of the bispecific antibody epcoritamab (for B-cell CD20 and T-cell CD3 antigens) to lenalidomide plus rituximab improved the objective response rate and progression-free...
Impact of Physical Activity on Fatigue, Quality of Life in Nonmetastatic Colorectal Cancer
Greater levels of physical activity in the first 2 years after a colorectal cancer diagnosis were associated with reduced cancer-related fatigue and improved quality of life in patients with nonmetastatic disease, according to findings from a prospective, multicenter, longitudinal analysis from a...
High Neighborhood Fast Food Expenditure and Early-Onset Colorectal Cancer
Studies show that while the overall rates of colorectal cancer are decreasing, for individuals younger than age 50, the incidence has risen by an alarming 50% since the mid-1990s. While the exact causes are unknown, poor diet and alcohol consumption are believed to be contributing factors. A study...
Most People Trust AI Less Than Physicians, Survey Finds
Two national surveys examining trust and acceptance of medical artificial intelligence (AI) have found that while most people are reluctant to use AI tools to diagnose their health condition, they see potential in the technology’s ability to help diagnose cancer. The findings, published by Sobolev...
Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer
In a meta-analysis reported in JAMA Oncology, Zaorsky et al found that longer durations of androgen-deprivation therapy given with definitive radiotherapy were associated with nonlinear relative benefits in patients with localized prostate cancer. Study Details The meta-analysis used...
A Novel Paradigm in Acute Kidney Injury: Congestive Nephropathy in RCC With IVC Thrombus
Researchers have proposed a new mechanism of acute kidney injury to account for patients with renal cell carcinoma (RCC) who have an inferior vena cava (IVC) tumor thrombus, according to findings presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 By analyzing...
Neoadjuvant SABR Improves Outcomes in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus
Tumor thrombus in the inferior vena cava (IVC) resulting from renal cell carcinoma (RCC) can be safely and effectively treated with stereotactic ablative radiation therapy (SABR) prior to surgery, according to findings from a phase II trial presented at the 26th Annual Meeting of the Society of...
FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection
On December 17, the U.S. Food and Drug Administration (FDA) approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant). PALOMA-3 The subcutaneous injection of ...
IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer
Circulating tumor DNA (ctDNA) status after radical cystectomy may be able to effectively guide adjuvant treatment decisions for patients with muscle-invasive bladder cancer, according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 Results of an exploratory...
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated strong high-grade recurrence-free survival rates in patients with high-risk, papillary-only, bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer, according to data presented at the 26th Annual...
Disease-Free Survival With Gemcitabine Intravesical System in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual...
Intravesical Oncolytic Adenovirus Delivers High Complete Response Rates in BCG-Naive, High-Risk, Non–Muscle-Invasive Bladder Cancer With Carcinoma in Situ
Intravesical cretostimogene grenadenorepvec (CG0070) monotherapy demonstrated a high overall complete response rate in patients with high-risk, bacillus Calmette-Guérin (BCG)-naive non–muscle-invasive bladder cancer with carcinoma in situ, according to early results from Cohort A of the phase II...
KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder...
10-Year Outcomes With Adjuvant Metronomic Capecitabine in Early Triple-Negative Breast Cancer
In a 10-year update of a Chinese phase III trial (SYSUCC-001) reported in The Lancet Oncology, Yuan et al found that the sequential addition of metronomic capecitabine to standard adjuvant therapy continued to be associated with significant benefits in patients who had undergone surgery for early...
Distant Disease–Free Survival as a Surrogate for Overall Survival in Trials of Neoadjuvant Therapy in Early Breast Cancer
In a pooled analysis of randomized neoadjuvant trials reported in The Lancet Oncology, Conforti et al found that distant disease–free survival was a “robust” surrogate endpoint for overall survival in many patients with early breast cancer. Study Details The analysis included individual patient...
Addition of Eflornithine to Lomustine in Patients With Recurrent Grade 3 Astrocytoma
As reported in the Journal of Clinical Oncology by Colman et al, the phase III STELLAR trial showed no difference in overall survival with the addition of eflornithine to lomustine in patients with recurrent grade 3 astrocytoma; however, marked progression-free survival and overall survival...
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
As reported in the Journal of Clinical Oncology by Tomasini et al, findings in a cohort of the early-phase CHRYSALIS-2 trial indicate activity of amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC). Study Details In the international trial, ...
Preoperative PAXG vs mFOLFIRINOX in Pancreatic Ductal Adenocarcinoma
As reported in The Lancet by Reni et al, analysis of the first randomization in an Italian 2 × 2 factorial phase III trial (PACT-21 CASSANDRA) has shown better event-free survival with preoperative PAXG (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) vs mFOLFIRINOX (modified fluorouracil,...
Tanning Bed Exposure and Melanoma Risks
Research has elucidated how radiation from tanning beds increases the mutation burden across a broad area of melanocytes, thereby significantly raising the risk of developing melanoma. Findings published in Science Advances show that individuals who used tanning beds had a 2.85-fold higher risk of...
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
As reported in the Journal of Clinical Oncology, Maurer et al have developed FLIPI24, a modern prognostic model for newly diagnosed follicular lymphoma. As stated by the investigators, “Although most patients with … [follicular lymphoma] can expect an indolent course, progressive lymphoma remains...
FDA Approves Regimen for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer
On December 12, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor niraparib and the hormone therapy abiraterone acetate (Akeega) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer, as determined by ...
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?
Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's risk of distant recurrence, according to an analysis presented at the 2025 San Antonio Breast Cancer...
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
The addition of the investigational monoclonal antibody ianalumab to eltrombopag extended the time to treatment failure in patients with primary immune thrombocytopenia (ITP) after prior treatment with corticosteroids, according to findings from the phase III VAYHIT2 trial presented at the 2025...
Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors
New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alone, while real acupuncture improves objective measures of cognitive performance better than sham...
Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer
Similar recurrence and regional recurrence-free survival rates were observed at 5 years with or without a sentinel lymph node biopsy in patients with clinically node-negative cT1-2 breast cancer treated with breast-conserving therapy, according to findings from the phase III BOOG 2013-08 trial...
Oral SERD Improves Disease-Free Survival Over Standard of Care for Patients With Early-Stage Breast Cancer
The investigational oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease–free survival compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor-positive,...
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and surgical planning, according to findings from the phase III Alliance A011104/ACRIN 6694 trial...
HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patients with HER2-positive metastatic breast cancer, according to findings presented at the 2025 San...
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated...
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
The noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to findings from a randomized...
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed a standard treatment strategy of imatinib plus...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Ironically, Smoking May Have Saved My Life
I was diagnosed with stage IV non-small cell lung (NSCLC) adenocarcinoma on August 1, 2013—World Lung Cancer Day. If it hadn’t been for an article that caught my eye the year before about the recommendation from the United States Preventive Services Task Force that all men aged 65 to 75 who have...
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin,...
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte (TIL) cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
Updated findings from the phase II iMMagine-1 study show that anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for relapsed or refractory multiple myeloma, continues to deliver high response rates with a reassuring safety profile. Researchers from The University of Texas ...
Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma
When epcoritamab was added to lenalidomide and rituximab, response rates were significantly higher and progression-free survival was prolonged for patients with follicular lymphoma treated in the second-line setting or beyond, according to findings from the phase III EPCORE FL-1 trial presented at...
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
The combination of azacitidine and venetoclax led to improved efficacy outcomes with fewer complications than standard intensive induction chemotherapy as upfront treatment for patients with acute myeloid leukemia (AML), according to trial findings presented at the 2025 American Society of...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
UICC’s World Cancer Declaration 2025–2035
The Union for International Cancer Control (UICC) published its World Cancer Declaration 2025–2035 framework on November 19, 2025.1 The declaration urges governments and policymakers to take decisive action to reduce the global burden of cancer; promote equitable access to prevention, diagnosis,...
ASCO and AI in Oncology: Rooted in Human-Centered Care
ASCO’s mission to conquer cancer through research, education, and promotion of the highest quality patient care requires curiosity, open-mindedness, and an evidence-based approach to emerging technologies. ASCO is committed to helping the oncology community understand, develop, apply, and monitor...
High Risk of Metastatic Recurrence Among Young Patients With Cancer
A new study of adolescents and young adults (AYAs) with seven common cancers reveals that nearly one in ten patients diagnosed with non-metastatic disease later develop metastatic recurrence. The information was shared in a news statement from the UC Davis Comprehensive Cancer Center. Scientists at ...
The Diagnosis I Couldn’t Deliver: An Oncologist’s Journey Between Roles
As a medical oncologist and palliative care physician, I have spent years preparing for difficult conversations. I’ve guided patients and families through the uncertainty of cancer, helped them navigate complex decisions, and sought meaning amid shifting prognoses. As an academic, I teach future...
